社论：用于肺癌治疗的表皮生长因子受体酪氨酸激酶抑制剂：研发、应用及副作用 - Suppr

Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects.

作者信息

Shen Qinglin, Tang Hexiao, Chen Shengxi

机构信息

Department of Oncology, Jiangxi Provincial People's Hospital, the First Affiliated Hospital of Nanchang Medical College, Nanchang, China.

Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.

出版信息

Front Oncol. 2025 May 22;15:1617788. doi: 10.3389/fonc.2025.1617788. eCollection 2025.

DOI:10.3389/fonc.2025.1617788

PMID:40475016

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12137224/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b59e/12137224/98275eb1a213/fonc-15-1617788-g001.jpg

相似文献

Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects.社论：用于肺癌治疗的表皮生长因子受体酪氨酸激酶抑制剂：研发、应用及副作用

Front Oncol. 2025 May 22;15:1617788. doi: 10.3389/fonc.2025.1617788. eCollection 2025.

Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.液体活检靶向捕获测序分析在提高非小细胞肺癌酪氨酸激酶抑制剂精准治疗中的应用。

BMJ Open Respir Res. 2022 Jan;9(1). doi: 10.1136/bmjresp-2021-001154.

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway.二甲双胍通过AMPK/ERK/NF-κB信号通路克服EGFR突变型肺癌对EGFR酪氨酸激酶抑制剂的获得性耐药。

Front Oncol. 2020 Sep 10;10:1605. doi: 10.3389/fonc.2020.01605. eCollection 2020.

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.阿法替尼作为 EGFR 突变阳性 NSCLC 亚洲患者的一线治疗：真实世界证据的叙述性综述。

Adv Ther. 2021 May;38(5):2038-2053. doi: 10.1007/s12325-021-01696-9. Epub 2021 Mar 17.

Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.表皮生长因子受体酪氨酸激酶抑制剂与TEAD抑制剂联合治疗增强表皮生长因子受体突变阳性肺癌的肿瘤抑制作用。

Mol Cancer Ther. 2024 Apr 2;23(4):564-576. doi: 10.1158/1535-7163.MCT-23-0371.

[Non-small Cell Lung Cancer Cell Line PC-9 Drug-resistant Mutant Cell Line  Establishment and Validation of Their Sensitivity to EGFR Inhibitors].[非小细胞肺癌细胞系PC-9耐药突变细胞系的建立及其对EGFR抑制剂敏感性的验证]

Zhongguo Fei Ai Za Zhi. 2024 Nov 20;27(11):815-825. doi: 10.3779/j.issn.1009-3419.2024.101.31.

Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.立体定向放射外科联合表皮生长因子酪氨酸激酶抑制剂治疗非小细胞肺癌脑转移的临床研究

J BUON. 2019 Mar-Apr;24(2):578-584.

[Research Progress on the Combination Therapy of EGFR-TKIs and Metformin  in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer].[表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）与二甲双胍联合治疗非小细胞肺癌EGFR-TKIs获得性耐药的研究进展]

Zhongguo Fei Ai Za Zhi. 2023 Nov 20;26(11):874-880. doi: 10.3779/j.issn.1009-3419.2023.106.22.

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities.PIK3CA 突变作为非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的驱动因素：临床挑战与机遇。

Pharmacol Res. 2024 Apr;202:107123. doi: 10.1016/j.phrs.2024.107123. Epub 2024 Mar 2.

Development of personalized treatments in lung cancer: focusing on the mutations and beyond.肺癌个性化治疗的发展：聚焦于突变及其他方面。

Lung Cancer (Auckl). 2013 Aug 14;4:43-53. doi: 10.2147/LCTT.S49603. eCollection 2013.

本文引用的文献

Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer.表皮生长因子受体调节谱系可塑性，推动向小细胞肺癌的转化。

Biochem Biophys Res Commun. 2023 Nov 12;681:218-224. doi: 10.1016/j.bbrc.2023.09.047. Epub 2023 Sep 27.

Editorial: Cancer treatment and early detection targeting HER receptors, Volume II.社论：靶向HER受体的癌症治疗与早期检测，第二卷

Front Mol Biosci. 2023 Jun 22;10:1229765. doi: 10.3389/fmolb.2023.1229765. eCollection 2023.

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.奥希替尼耐药的表皮生长因子受体突变型非小细胞肺癌患者的治疗策略。

J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4.

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors.社论：针对HER受体的癌症治疗与早期检测

Front Mol Biosci. 2022 Jun 15;9:940055. doi: 10.3389/fmolb.2022.940055. eCollection 2022.

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.表皮生长因子受体突变介导非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂的耐药性：从分子机制到临床研究。

Pharmacol Res. 2021 May;167:105583. doi: 10.1016/j.phrs.2021.105583. Epub 2021 Mar 26.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.表皮生长因子受体中的激活突变是非小细胞肺癌对吉非替尼产生反应的基础。

N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献